# PD-L1 Antibody

Catalog No: #P1013

Package Size: #P1013-1 0.1ml #P1013-2 1ml Orders: order



Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com

## Description


| Product Name       | PD-L1 Antibody                             |
|--------------------|--|
| Host Species       | Rabbit                                     |
| Clonality          | Monoclonal                                 |
| Clone No.          | IHC411                                     |
| Applications       | IHC  |
| Species Reactivity | Human                                      |
| Formulation        | Tris Buffer, pH 7.3 - 7.7, with 1% BSA and |
| Storage            | Store at 2-8C. Do not freeze.              |

### **Application Details**


Recommended

working dilution range:1:100 - 1:200


### **Images**



PD-L1 Antibody (P1013) on Lung cancer



PD-L1 Antibody (P1013) on Lung Cancer - 20X



#### **Product Description**

Programmed Death-Ligand 1 (PD-L1), also known as CD274 or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8+ T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, and, in ovarian cancer, higher expression of this protein has lead to significantly poorer prognosis. PD-L1 has also been linked to systemic lupus erythematosus and cutaneous melanoma. When considered in adjunct with CD8+ tumor-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.

#### References

Ostrand-Rosenberg S, et al. J Immunol. 2014; 193:3835-41.

Tokito T, et al. Eur J Cancer. 2016; 55:7-14.

Park IH, et al. Clin Breast Cancer. 2016; 16:51-8.

Kakavand H, et al. Mod Pathol. 2015; 28: 1535-44.

Xia B, et al. Immunotherapy. 2016; 8:279-98.

Patel SP, et al. Mol Cancer Ther. 2015; 14:847-56.

Singh BP, et al. Cancers (Basel). 2016; 8.

Chemnitz JM, et al. J Immunol. 2004; 173:945C54.

Thompson RH, et al. Proc Natl Acad Sci USA. 2004; 101:17174C9.

Hamanishi J, et al. Proc Natl Acad Sci USA. 2007; 104:3360C5.

Mozaffarian N, et al. Rheumatology, 2008; 47:1335C41.

Note: This product is for in vitro research use only